619 related articles for article (PubMed ID: 23787722)
1. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
Filippatos G; Farmakis D; Colet JC; Dickstein K; Lüscher TF; Willenheimer R; Parissis J; Gaudesius G; Mori C; von Eisenhart Rothe B; Greenlaw N; Ford I; Ponikowski P; Anker SD
Eur J Heart Fail; 2013 Nov; 15(11):1267-76. PubMed ID: 23787722
[TBL] [Abstract][Full Text] [Related]
2. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
[TBL] [Abstract][Full Text] [Related]
3. Ferric carboxymaltose in patients with heart failure and iron deficiency.
Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
Anker SD; Colet JC; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Mori C; von Eisenhart Rothe B; Pocock S; Poole-Wilson PA; Ponikowski P;
Eur J Heart Fail; 2009 Nov; 11(11):1084-91. PubMed ID: 19875408
[TBL] [Abstract][Full Text] [Related]
5. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
[TBL] [Abstract][Full Text] [Related]
6. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.
Ponikowski P; van Veldhuisen DJ; Comin-Colet J; Ertl G; Komajda M; Mareev V; McDonagh T; Parkhomenko A; Tavazzi L; Levesque V; Mori C; Roubert B; Filippatos G; Ruschitzka F; Anker SD;
Eur Heart J; 2015 Mar; 36(11):657-68. PubMed ID: 25176939
[TBL] [Abstract][Full Text] [Related]
8. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
9. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
Gutzwiller FS; Pfeil AM; Comin-Colet J; Ponikowski P; Filippatos G; Mori C; Braunhofer PG; Szucs TD; Schwenkglenks M; Anker SD
Int J Cardiol; 2013 Oct; 168(4):3878-83. PubMed ID: 23870642
[TBL] [Abstract][Full Text] [Related]
10. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
[TBL] [Abstract][Full Text] [Related]
11. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P; Kirwan BA; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A; Khintibidze I; Kragten H; Martinez FA; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parkhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Lewis BS; Comin-Colet J; von Haehling S; Cohen-Solal A; Danchin N; Doehner W; Dargie HJ; Motro M; Butler J; Friede T; Jensen KH; Pocock S; Jankowska EA;
Lancet; 2020 Dec; 396(10266):1895-1904. PubMed ID: 33197395
[TBL] [Abstract][Full Text] [Related]
12. [Anaemia and iron deficiency in clinical practice:from cardiology to gastroenterology and beyond].
Češka R
Vnitr Lek; 2014 Dec; 60(12):1033-9. PubMed ID: 25692829
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
[TBL] [Abstract][Full Text] [Related]
14. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
15. Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.
Okonko DO; Jouhra F; Abu-Own H; Filippatos G; Colet JC; Suki C; Mori C; Ponikowski P; Anker SD;
ESC Heart Fail; 2019 Aug; 6(4):621-628. PubMed ID: 31148411
[TBL] [Abstract][Full Text] [Related]
16. Iron substitution in the treatment of chronic heart failure.
Gstrein C; Meyer M; Anabitarte P
Swiss Med Wkly; 2017; 147():w14453. PubMed ID: 28695549
[TBL] [Abstract][Full Text] [Related]
17. Ferric Carboxymaltose: A Review in Iron Deficiency.
Scott LJ
Drugs; 2018 Mar; 78(4):479-493. PubMed ID: 29532438
[TBL] [Abstract][Full Text] [Related]
18. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.
Becher PM; Schrage B; Benson L; Fudim M; Corovic Cabrera C; Dahlström U; Rosano GMC; Jankowska EA; Anker SD; Lund LH; Savarese G
Eur J Heart Fail; 2021 Nov; 23(11):1844-1854. PubMed ID: 34476878
[TBL] [Abstract][Full Text] [Related]
19. Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia.
Cooper TJ; Anker SD; Comin-Colet J; Filippatos G; Lainscak M; Lüscher TF; Mori C; Johnson P; Ponikowski P; Dickstein K
Am J Cardiol; 2016 May; 117(9):1482-7. PubMed ID: 27015889
[TBL] [Abstract][Full Text] [Related]
20. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF).
Yeo TJ; Yeo PSD; Hadi FA; Cushway T; Lee KY; Yin FF; Ching A; Li R; Loh SY; Lim SL; Wong RC; Tai BC; Richards AM; Lam CSP
ESC Heart Fail; 2018 Apr; 5(2):344-353. PubMed ID: 29345426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
